Secukinumab for active ankylosing spondylitis in Chinese adults
Treatments studied
Part of Bones, joints & muscles clinical trials.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ankylosing spondylitis, based on specific medical criteria
- Your symptoms are currently active: back pain and overall disease activity must be above set cutoffs at screening and baseline
- You tried at least two NSAIDs for at least 4 weeks total at maximum tolerated doses, or you could not take NSAIDs
- If you use certain other arthritis medicines (like methotrexate, sulfasalazine, hydroxychloroquine, or leflunomide), your dose must be stable for at least 28 days (and you can’t use methotrexate with leflunomide together)
- If you use steroids or pain medicines, the dose must be stable for specific time windows before baseline
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining traditional Chinese medicine with standard Western treatments can help ankylosing spondylitis (a condition causing spine stiffness and inflammation) work better and improve your quality of life. Researchers will follow patients over time to see how well this combined approach works.
This study tests if combining traditional Chinese medicine with standard Western medicine can better treat ankylosing spondylitis. The goal is to see if this approach can reduce inflammation and improve your symptoms, such as back pain and stiffness.
This study tracks how axial spondyloarthritis progresses over time in Chinese patients. It helps doctors understand the natural course of the disease and improve care.
This trial tests whether combining two biologic medications (adalimumab and secukinumab) can better relieve symptoms of ankylosing spondylitis, a type of arthritis that affects the spine. It may help if you have not responded well to standard nonsteroidal anti-inflammatory drugs (NSAIDs) and you have active disease.
This study tests the safety of a drug called secukinumab (given as an injection under the skin) for people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It aims to see if this treatment is safe for adults in India with this condition.
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
Hear when a new Ankylosing Spondylitis (AS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.